Renal papillary calcification and the development of calcium oxalate monohydrate papillary renal calculi: A case series study

BMC Urology

Volumn 13, Issue , 2013, Pages

  Grases, Fèlix ^a   Costa Bauzá, Antonia ^a   Prieto, Rafel M ^a   Conte, Antonio ^a   Servera, Antonio ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Calcium oxalate monohydrate; Hydroxyapatite; Kidney papilla; Pathologic calcification; Renal calculi

Indexed keywords

CALCIUM; CITRIC ACID; FUROSEMIDE; HYDROXYAPATITE; MAGNESIUM; METHOTREXATE; OMEPRAZOLE; OXALIC ACID; PHOSPHORUS; URATE; WHEWELLITE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CASE REPORT; FEMALE; HUMAN; KIDNEY PAPILLA; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALE; MEDICAL RECORD REVIEW; NEPHROLITHIASIS; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; URINALYSIS;

ADULT; AGED; CALCINOSIS; CALCIUM; CALCIUM OXALATE; CRYSTALLIZATION; DURAPATITE; FEMALE; HUMANS; KIDNEY CALCULI; KIDNEY DISEASES; KIDNEY MEDULLA; MAGNESIUM; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PHOSPHORUS; RETROSPECTIVE STUDIES;

EID: 84874668125     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-14     Document Type: Article

References (39)

1. How much interdisciplinarity is required to understand vascular calcifications? Formulation of four basic principles of vascular calcification. Epple M, Lanzer P, Z Kardiol 2001 90 Suppl III 2 5 11826817 (Pubitemid 32291158)
2. Phosphate-induced vascular calcification, role of pyrophosphate and osteopontin. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC, J Am Soc Nephrol 2004 15 1392 1401 10.1097/01.ASN.0000128955.83129.9C 15153550 (Pubitemid 38679664)
3. Mechanism of calcification, inhibitory role of pyrophosphate. Fleisch H, Bisaz S, Nature 1962 195 911 14466639
4. Bisphosphonates and atherosclerosis, why? Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M, Lupus 2005 14 773 779 10.1191/0961203305lu2219oa 16218486 (Pubitemid 41413310)
5. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Price PA, Faus SA, Williamson MK, Arterioscler Thromb Vasc Biol 2001 21 817 824 10.1161/01.ATV.21.5.817 11348880 (Pubitemid 32448773)
6. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. Price PA, Buckley JR, Williamson MK, J Nutr 2001 131 2910 2915 11694617 (Pubitemid 33063122)
7. Phytate (myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Grases F, Sanchis P, Perello J, Isern B, Prieto RM, Fernandez-Palomeque C, Fiol M, Bonnin O, Torres JJ, Front Biosci 2006 11 136 142 10.2741/1786 16146720 (Pubitemid 43253481)
8. Effect of crystallization inhibitors on vascular calcifications induced by vitamin D, A Pilot Study in Sprague-Dawley Rats. Grases F, Sanchis P, Perelló J, Isern B, Prieto RM, Fernández-Palomeque C, Torres JJ, Circ J 2007 71 1152 1156 10.1253/circj.71.1152 17587727 (Pubitemid 46998036)
9. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E, J Bone Miner Res 2006 21 484 490 16491297
10. Osteoclast adhesion and activity on synthetic hydroxyapatite, carbonated hydroxyapatite, and natural calcium carbonate, relationship to surface energies. Redey SA, Razzouk S, Rey C, Bernache-Assollant D, Leroy G, Nardin M, Cournot G, J Biomed Mater Res 1999 45 140 147 10.1002/(SICI)1097-4636(199905)45:2<140:: AID-JBM9>3.0.CO;2-I 10397968 (Pubitemid 29114162)
11. Osteopontin is associated with bioprosthetic heart valve calcification in humans. Shen M, Marie P, Farge D, Carpentier S, De Pollak C, Hott M, Chen L, Martinet B, Carpentier A, C R Acad Sci III 1997 320 49 57 10.1016/S0764-4469(99) 80086-9 9099263 (Pubitemid 27154103)
12. Changes of HAp/PLLA biocomposites and tissue reaction after subcutaneous implantation. Najman S, Dordevic L, Savic V, Ignjatovic N, Plavsic M, Uskokovic D, Facta Universitatis 2003 10 131 134
13. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways, a vicious cycle of inflammation and arterial calcification? Nadra I, Mason JC, Philippidis P, Florey O, Smythe CDW, McCarthy GM, Landis RC, Haskard DO, Circ Res 2005 96 1248 1256 10.1161/01.RES.0000171451.88616.c2 15905460 (Pubitemid 40962102)
14. Basic calcium phosphate crystals stimulate the endocytotic activity of cells-inhibition by anti-calcification agents. Sun YB, Zeng XR, Wenger L, Cheung HS, Biochem Biophys Res Commun 2003 312 1053 1059 10.1016/j.bbrc.2003.11.048 14651978 (Pubitemid 37490922)
15. Simple classification of renal calculi closely related to their micromorphology and etiology. Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A, Clin Chim Acta 2002 22 29 36 (Pubitemid 34718059)
16. Physicochemical aspects of urolithiasis. Finlayson B, Kidney Int 1978 13 344 360 10.1038/ki.1978.53 351263 (Pubitemid 8349988)
17. Activity products in stone-forming and non-stone-forming urine. Robertson WG, Peacock M, Nordin BEC, Clin Sci 1968 34 579 594 5666884
18. Origin and growth of renal calculi. Randall A, Ann Surg 1937 105 1009 1027 10.1097/00000658-193706000-00014 17856988
19. The riddle of Randall's plaques. Prien EL, J Urol 1975 114 500 507 1235369
20. Endoscopic mapping of renal papillae for Randalls plaques in patients with urinary stone disease. Low RK, Stoller ML ML, J Urol 1997 158 2062 2064 10.1016/S0022-5347(01)68153-9 9366312 (Pubitemid 27481327)
21. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M, J Clin Invest 2003 111 607 616 12618515 (Pubitemid 36278579)
22. Stone formation is proportional to papillary surface coverage by Randall's plaque. Kim SC, Coe FL, Tinmouth WW, Kuo RL, Paterson RF, Parks JH, Munch LC, Evan AP, Lingeman JE, J Urol 2005 173 117 119 10.1097/01.ju. 0000147270.68481.ce 15592050 (Pubitemid 39627688)
23. Nephrolithiasis and nephrocalcinosis in rats with small bowel resection. Oconnor RC, Worcester EM, Evan AP, Meehan S, Kuznetsov D, Laven B, Sommer AJ, Bledsoe SB, Parks JH, Coe FL, Grynpas M, Gerber GS, Urol Res 2005 33 105 115 10.1007/s00240-004-0460-4 15815943 (Pubitemid 40921949)
24. Apatite plaque particles in inner medulla ofkidneys of calcium oxalate stone formers: osteopontin localization. Evan AP, Coe FL, Rittling SR, Bledsoe SM, Shao T, Lingeman JE, Worcester EM, Kidney Int 2005 68 145 154 10.1111/j.1523-1755.2005.00388.x 15954903 (Pubitemid 43181371)
25. Analytical study of renal calculi. A new insight. Grases F, García-Ferragut L, Costa-Bauzá A, Rec Res Dev Pure Appl Anal Chem 1998 1 187 206
26. Origin and types of calcium oxalate monohydrate papillary renal calculi. Grases F, Costa-Bauzá A, Gomila I, Conte A, Urology 2010 76 1339 1345 10.1016/j.urology.2010.02.022 20466410
27. Mechanism of formation of human calcium oxalate renal stones on Randalls plaque. Evan AP, Coe FL, Lingeman JE, Shao Y, Sommer AJ, Bledsoe SB, Anderson JC, Worcester EM, Anat Rec 2007 290 1315 1323 10.1002/ar.20580 (Pubitemid 47573203)
28. Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Evan AP, Weinman EJ, Wu XR, Lingeman JE, Worcester EM, Coe FL, Urol Res 2010 38 439 452 10.1007/s00240-010-0330-1 21063698
29. Heterogeneous nucleation of hydroxyapatite on protein, structural effect of silk sericin. Takeuchi A, Ohtsuki C, Miyazaki T, Kamitakahara M, Ogata S, Yamazaki M, Furutani Y, Kinoshita H, Tanihara M, J R Soc Interface 2005 2 373 378 10.1098/rsif.2005.0052 16849195
30. Mineralization. Anderson HC, Morris DC, Physiology and Pharmacology of Bone New York: Springer Verlag, Mundy GR, Martin TJ, 1993 267 298
31. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM, Am J Pathol 2002 161 2035 2046 10.1016/S0002-9440(10)64482-3 12466120 (Pubitemid 35434850)
32. Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium binding proteins. Romberg RW, Werness PG, Riggs BL, Mann KG, Biochemistry 1986 25 1176 1180 10.1021/bi00353a035 3008822 (Pubitemid 16099515)
33. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Boskey AL, Maresca M, Ullrich W, Doty SD, Butler WT, Prince CW, Bone Miner 1993 22 147 159 10.1016/S0169-6009(08)80225-5 8251766 (Pubitemid 23272798)
34. An oxalate-binding protein with crystal growth promoter activity from human kidney stone matrix. Govindaraj A, Selvam R, BJU Int 2002 90 336 344 10.1046/j.1464-410X.2002.02849.x 12133075 (Pubitemid 34989086)
35. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Yamate Y, Kohri K, Umekawa T, Amasaki N, Amasaki N, Isikawa Y, Iguchi M, Kurita T, Eur Urol 1996 30 388 393 8931975 (Pubitemid 26362884)
36. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Lieske JC, Toback FG, Deganello S, Kidney Int 2001 60 1784 1791 10.1046/j.1523-1755.2001.00015.x 11703596 (Pubitemid 32999983)
37. Phytate acts as an inhibitor in formation of renal calculi. Grases F, Isern B, Sanchis P, Perello J, Torres JJ, Costa-Bauza A, Front Biosci 2007 12 2580 2587 10.2741/2256 17127264
38. Inhibitors of crystal growth of hydroxyapatite, a constant composition approach. Wilson JW, Werness PG, Smith LH, J Urol 1985 134 1255 1258 2997488 (Pubitemid 16207048)
39. A retrospective evaluation of Randalls plaque theory of nephrolithiasis with CT attenuation values. Bhuskute NM, Yap WW, Wah TM, Eur J Radiol 2009 72 470 472 10.1016/j.ejrad.2008.09.009 18947952